Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of -0.01 is 108% below its 5-year average of 0.17, near the low end of its 5-year range (-0.02–0.47).
As of the fiscal period ended Tuesday, June 30, 2026. 34.20% below its 12-month average of -0.01.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): -0.01.
DEBT TO EQUITY RATIO
-0.01
DEBT TO EQUITY RATIO AVG TTM
-0.01
DEBT TO EQUITY RATIO AVG 3Y
0.19
DEBT TO EQUITY RATIO AVG 5Y
0.17
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-34.20%
CURRENT VS 3Y AVG
-107.63%
CURRENT VS 5Y AVG
-108.28%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 774 covered companies
CURRENT VS SECTOR MEDIAN
-113.06%
vs the sector median at left
Vor Biopharma Inc.
Market Cap
$992.14M
Debt to Equity Ratio
-0.01
TTM Avg
-0.01
3Y Avg
0.19
5Y Avg
0.17
Market Cap
$996.65M
Debt to Equity Ratio
0.23
TTM Avg
0.21
3Y Avg
0.27
5Y Avg
0.36
Market Cap
$998.69M
Debt to Equity Ratio
0.01
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.01
Market Cap
$982.46M
Debt to Equity Ratio
0.02
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.01
Market Cap
$981.66M
Debt to Equity Ratio
0.52
TTM Avg
0.95
3Y Avg
0.70
5Y Avg
0.50
Market Cap
$978.09M
Debt to Equity Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$973.93M
Debt to Equity Ratio
0.61
TTM Avg
0.74
3Y Avg
0.79
5Y Avg
0.93
Market Cap
$1.02B
Debt to Equity Ratio
0.08
TTM Avg
0.07
3Y Avg
0.05
5Y Avg
0.04
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vor Biopharma Inc. (VOR) | $992.14M | -0.01 | -0.01 | 0.19 | 0.17 |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $996.65M | 0.23 | 0.21 | 0.27 | 0.36 |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $998.69M | 0.01 | 0.01 | 0.01 | 0.01 |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $982.46M | 0.02 | 0.01 | 0.01 | 0.01 |
| MeiraGTx Holdings plc (MGTX)vs › | $981.66M | 0.52 | 0.95 | 0.70 | 0.50 |
| Immatics N.V. (IMTX)vs › | $1.01B | 0.04 | 0.03 | 0.05 | 0.11 |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $978.09M | N/A | N/A | N/A | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $973.93M | 0.61 | 0.74 | 0.79 | 0.93 |
| Castle Biosciences, Inc. (CSTL)vs › | $1.02B | 0.08 | 0.07 | 0.05 | 0.04 |
| Janux Therapeutics, Inc. (JANX)vs › | $1.02B | 0.02 | 0.02 | 0.05 | 0.03 |
Debt/Equity
-0.01
Current Ratio
19.15
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | -0.01 |
| 2026-03-31 | -0.02 |
| 2025-12-31 | -0.02 |
| 2025-09-30 | 0.00 |
| 2025-06-30 | 0.00 |
| 2025-03-31 | 0.47 |
| 2024-12-31 | 0.33 |
| 2024-09-30 | 0.45 |
| 2024-06-30 | 0.34 |
| 2024-03-31 | 0.28 |
| 2023-12-31 | 0.24 |
| 2023-09-30 | 0.21 |
| 2023-06-30 | 0.18 |
| 2023-03-31 | 0.17 |
| 2022-12-31 | 0.16 |
| 2022-09-30 | 0.25 |
| 2022-06-30 | 0.24 |
| 2022-03-31 | 0.15 |
| 2021-12-31 | 0.08 |
| 2021-09-30 | 0.08 |
| 2021-06-30 | 0.07 |
| 2021-03-31 | 0.07 |
| 2020-12-31 | 0.38 |
| 2020-09-30 | 0.29 |
| 2020-06-30 | 0.24 |
| 2020-03-31 | 0.00 |
| 2019-12-31 | 0.00 |
| 2019-09-30 | 0.00 |
| 2019-06-30 | 0.00 |
| 2019-03-31 | 0.00 |
